Please assess the completion status of the following clinical trial:

Trial Title: Triptorelin for Ovary Protection in Childhood Onset Lupus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Females under the age of 21 and non-pregnant~* Tanner stage of 2 or above as determined by physical examination of breast stage~* Diagnosis with SLE using the updated American College of Rheumatology (ACR) Classification Criteria for SLE 1~* Severe SLE requiring cyclophosphamide therapy~* Bone mineral density z-score \> - 2.0~* Must be using a medically acceptable form of birth control during the study and must not be pregnant at the screening visit~* No clinically significant abnormal findings other than those consistent with the diagnosis of childhood-onset SLE (cSLE) on the physical examination, medical history or clinical laboratory results during screening~* Currently on any combination of medication but must not have been treated with more than one dose of cyclophosphamide or other gonadotoxic medications in the past~* Voluntary consent or, if under the age of consent, assent to participate in this study with permission by a legal guardian~Exclusion Criteria:~* Male patients of any age~* Female patients with a Tanner stage of 1~* Positive blood pregnancy test at screening or taking oral or injectable birth-control medications~* Prior exposure to more than one dose of gonadotoxic medications including cyclophosphamide~* History of allergic or adverse response to triptorelin~* Diagnosed with hypogonadism prior to cyclophosphamide exposure~* Acutely life-threatening disease activity that prohibits inclusion in a clinical trial~* History of clinically significant gastrointestinal tract, renal, hepatic, endocrine, oncologic, pulmonary (asthma accepted), or cardiovascular disease; or a history of tuberculosis, epilepsy, diabetes, depression, psychosis, or any other non-cSLE condition, which in the opinion of the physician, would jeopardize the safety of the subject or impact the validity of the study results~* Patient age 18 years of younger with severe depression as defined by a CDI (Children's Depression Inventory) score of \> 23 or a patient age 19 to 21 years with severe depression as defined by a BDI (Beck's Depression Inventory) score \> 29~* Patient admits to suicidal thoughts at screening visit~* Bone mineral density lower than z = -2.0.

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Triptorelin T1 (Type: EXPERIMENTAL): Triptorelin Pamoate 25 μg/kg body weight
- Triptorelin T2 (Type: EXPERIMENTAL): Triptorelin Pamoate 50 μg/kg body weight
- Triptorelin T3 (Type: EXPERIMENTAL): Triptorelin Pamoate 75 μg/kg body weight T3
- Triptorelin T4 (Type: EXPERIMENTAL): Triptorelin Pamoate 100 μg/kg body weight T4
- Placebo (Type: PLACEBO_COMPARATOR): Normal Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).